Technical Analysis for ETX - E-Therapeutics Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.60% | |
| Lower Bollinger Band Walk | Weakness | 1.60% | |
| Inside Day | Range Contraction | 1.60% | |
| Wide Bands | Range Expansion | 1.60% | |
| Gapped Down | Weakness | 1.60% | |
| 20 DMA Resistance | Bearish | -4.88% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.88% | |
| Slingshot Bearish | Bearish Swing Setup | -4.88% | |
| Stochastic Buy Signal | Bullish | -4.88% | |
| Lower Bollinger Band Walk | Weakness | -4.88% |
| Alert | Time |
|---|---|
| Gap Up Closed | about 1 hour ago |
| Non-ADX 1,2,3,4 Bearish Retracement Entry | about 2 hours ago |
| Fell Below Previous Day's Low | about 2 hours ago |
| Down 5% | about 2 hours ago |
| Down 3% | about 2 hours ago |
Get this analysis on your stocks daily!
E-Therapeutics Plc Description
e-Therapeutics plc is a United Kingdom-based drug discovery and development company. The Company's discovery platform is based on the network of pharmacology and chemical biology. The Company operates in the business segment of drug discovery and development. The Company applies its platform to the discovery of new drug candidates. The therapeutic focus of the Company's discovery activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and antivirals. The Company generates a range of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule antiTNFα; ETS2400, in Hedgehog pathway inhibition, and ETS5200, which delivers a range of spectrum antivirals. The Company has completed a Phase IIb study of a drug candidate for depressive disorder, ETS6103, as well as Phase I clinical trials in cancer for ETS2101.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Chemical Hedge Cancer Clinic Nature Biology Oncology Drug Discovery Clinical Trial Resistance Itn Antibiotic Therapies Biocides Pharmacology Cancer Therapies Erase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.0 |
| 52 Week Low | 8.0 |
| Average Volume | 819,030 |
| 200-Day Moving Average | 12.98 |
| 50-Day Moving Average | 12.21 |
| 20-Day Moving Average | 10.50 |
| 10-Day Moving Average | 9.69 |
| Average True Range | 1.18 |
| RSI (14) | 37.11 |
| ADX | 21.5 |
| +DI | 18.20 |
| -DI | 20.72 |
| Chandelier Exit (Long, 3 ATRs) | 9.01 |
| Chandelier Exit (Short, 3 ATRs) | 12.08 |
| Upper Bollinger Bands | 12.47 |
| Lower Bollinger Band | 8.52 |
| Percent B (%b) | 0.17 |
| BandWidth | 37.73 |
| MACD Line | -0.80 |
| MACD Signal Line | -0.75 |
| MACD Histogram | -0.0461 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.57 | ||||
| Resistance 3 (R3) | 10.56 | 10.08 | 10.34 | ||
| Resistance 2 (R2) | 10.08 | 9.72 | 10.09 | 10.26 | |
| Resistance 1 (R1) | 9.63 | 9.50 | 9.39 | 9.64 | 10.18 |
| Pivot Point | 9.15 | 9.15 | 9.03 | 9.16 | 9.15 |
| Support 1 (S1) | 8.70 | 8.79 | 8.46 | 8.71 | 8.17 |
| Support 2 (S2) | 8.22 | 8.57 | 8.23 | 8.09 | |
| Support 3 (S3) | 7.77 | 8.22 | 8.01 | ||
| Support 4 (S4) | 7.78 |
